Global Bioreactors Market Set To Grow To $1.4bn By 2022

07 August 2018
Pharma

Visiongain’ has launched a new pharma report Bioreactors Market Report : 5L-20L, 20L-200L, 200L-1500L, Above 1500L, Single-Use, Glass, Stainless Steel, Lab-Scale, Pilot-Scale, Full-Scale, R&D Departments, Biopharmaceutical Manufacturers, Contract Research Organizations, Other End-Users

The bioreactors market is driven by the increasing use of hybrid technologies, a rise in the rate of adoption of single-use technologies, increasing popularity of single-use bioreactor among biopharmaceutical organizations, and a significant growth in the biologics market. The global bioreactor market is dominated by the single-use bioreactors that hold a major share owing to their high usage in various applications. The main factor driving the increased usage of single-use bioreactors includes low upfront investment cost. There is a high adoption rate of single-use bioreactors owing to reduced capital expenditure costs due to the lower costs of cleaning and sterilizing bioreactors and enhancement of the flexibility in operations during drug manufacturing process.

The lead analyst of the report commented “Asia-Pacific and Rest of the World (RoW) are the emerging bioreactor markets. These regions hold tremendous potential to become the bioreactors market giants in the future. Asia-Pacific countries are estimated to demonstrate tremendous growth for bioreactors owing to the massive expansion of the biopharmaceutical sector in this region.

The rising interest of pharmaceutical organizations to enter the biopharmaceutical market will result in consolidation in the form of strategic alliances between contract manufacturing organizations (CMO’s) and large pharmaceutical/biotechnology organizations. This will result in increased investments and access to cutting-edge manufacturing technologies for CMOs. ”

Leading companies featured in the report include Sartorius AG, Thermo Fisher Scientific, Inc., Merck KGaA, GE Healthcare, Danaher Corporation, Eppendorf AG, Applikon Biotechnology Inc., Solaris Biotech, Bioengineering AG, and Infors HT

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes European Antibiotics Market Report 2021-2031

Penicillin segment holds majority of the market share owing to maximum prescription as well as the most generic manufacturers throughout the industry.

22 June 2021

Read

Visiongain Publishes Companion Diagnostics (CDx) Market Report 2021-2031

Over the last few years, companion diagnostics has gained widespread attention due to the technological advancements, growing demand for precision medicine, and accelerating demand for targeted therapy.

17 June 2021

Read

Visiongain Publishes Cellular Immunotherapy Market Report 2021-2031

Increasing prevalence of cancers and rising demand for advanced therapies for cancer treatment are the major factors driving the demand for cellular immunotherapies.

15 June 2021

Read

Visiongain Publishes Gene Therapy R&D Market Report 2021-2031

Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions.

14 June 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever